SCHEMBL6298345

SCHEMBL6298345

COc1ccc(C(=O)Nc2ccc3c(c2)CNCC3)cc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.61
PRKG1 Q13976 2/20 0.61
MELK Q14680 4/20 0.61
ITGB3 P05106 5/20 0.55
ITGA2 P17301 5/20 0.55
ITGA2B P08514 3/20 0.55
SLC2A1 P11166 1/20 0.54
F2 P00734 1/20 0.51
PLG P00747 1/20 0.51
PLAU P00749 1/20 0.51
PLAT P00750 1/20 0.51
KLKB1 P03952 1/20 0.51
PRSS1 P07477 1/20 0.51
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5874078 0.87 ROCK2 (0.47) ROCK2PRKG1MELKITGB3ITGA2
SCHEMBL5874032 0.84 ROCK2 (0.45) ROCK2PRKG1MELKSLC2A1MAPT
SCHEMBL5874146 0.84 ROCK2 (0.45) ROCK2PRKG1MELKITGB3ITGA2
SCHEMBL11729866 0.83 ROCK2 (0.77) ROCK2PRKG1MELKITGB3ITGA2
SCHEMBL7655328 0.82 MAPT (0.48) ROCK2PRKG1MAPTKDM4EMEN1
SCHEMBL6293655 0.82 ROCK2 (0.61) ROCK2MAPTKDM4EMEN1CYP2D6
SCHEMBL6605922 0.81 PDE4D (0.43) ROCK2PRKG1MELKMAPTKDM4E
SCHEMBL6601241 0.81 MAPT (0.44) ROCK2PRKG1MELKMAPTKDM4E
SCHEMBL3240060 0.81 ALDH1A1 (0.67) ROCK2PRKG1MELKITGB3ITGA2
SCHEMBL6602306 0.81 MAPT (0.45) ROCK2PRKG1MELKMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US claimed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US claimed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US claimed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885PRKG1 3911/4885MELK 2857/4885
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885PRKG1 3911/4885MELK 2857/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 ROCK2 4693/4885PRKG1 3928/4885MELK 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.